(Q34572852)

3 August 2017

1 reference

title

Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout (English)

1 reference

xanthine oxidase inhibitor

3 August 2017

0 references

author name string

Susan P Bruce

series ordinal

1

1 reference

PubMed ID

17132810

3 August 2017

language of work or name

English

0 references

publication date

28 November 2006

1 reference

Annals of Pharmacotherapy

3 August 2017

1 reference

3 August 2017

40

1 reference

3 August 2017

12

1 reference

3 August 2017

2187-2194

1 reference

3 August 2017

1 reference

Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia.

21 January 2018

1 reference

Allopurinol hypersensitivity syndrome: a review

21 January 2018

1 reference

Relation between adverse events associated with allopurinol and renal function in patients with gout

21 January 2018

1 reference

Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients

21 January 2018

1 reference

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

21 January 2018

1 reference

Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers

21 January 2018

1 reference

Clinical pharmacokinetics of allopurinol

21 January 2018

1 reference

Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout

21 January 2018

1 reference

PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment

21 January 2018

1 reference

The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

21 January 2018

1 reference

Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.

21 January 2018

1 reference

Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549.

21 January 2018

1 reference

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

21 January 2018

1 reference

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H121

1 reference

3 August 2017

1 reference

PubMed ID

17132810